SCHEMBL4128445

SCHEMBL4128445

O=C(O)Cc1ccc(NC2=NC(=O)C(=Cc3cc4ccccc4cc3OCc3ccc([N+](=O)[O-])cc3)S2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
POLB P06746 2/20 0.44
BLM P54132 1/20 0.44
PTP4A3 O75365 3/20 0.43
MAPT P10636 5/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PPIA P62937 2/20 0.40
USP2 O75604 1/20 0.40
CASP6 P55212 1/20 0.40
PPIF P30405 1/20 0.40
HPGD P15428 2/20 0.40
RECQL P46063 1/20 0.39
CTSV O60911 1/20 0.39
CTSL P07711 1/20 0.39
GAA P10253 1/20 0.38
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128440 1.00 MEN1 (0.44) MEN1KMT2APOLBBLMPTP4A3
SCHEMBL4125736 0.92 PTP4A3 (0.50) MEN1KMT2APOLBBLMPTP4A3
SCHEMBL4125733 0.92 PTP4A3 (0.50) MEN1KMT2APOLBBLMPTP4A3
SCHEMBL4131686 0.89 MEN1 (0.45) MEN1KMT2APOLBPTP4A3SMN1; SMN2
SCHEMBL4131690 0.89 MEN1 (0.45) MEN1KMT2APOLBPTP4A3SMN1; SMN2
SCHEMBL4127749 0.84 KMT2A (0.46) MEN1KMT2APOLBPTP4A3MAPT
SCHEMBL4133685 0.84 PTP4A3 (0.49) MEN1KMT2APOLBBLMPTP4A3
SCHEMBL4127754 0.84 KMT2A (0.46) MEN1KMT2APOLBPTP4A3MAPT
SCHEMBL4133682 0.84 PTP4A3 (0.49) MEN1KMT2APOLBBLMPTP4A3
SCHEMBL4137639 0.83 PTP4A3 (0.51) POLBPTP4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
CN-101268060-A Thiazolinone and oxazolinone compounds and application thereof as PTP1B inhibitor TORRENT PHARMACEUTICALS LTD (IN) 2008-09-17 CN claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
CN-101268060-A Thiazolinone and oxazolinone compounds and application thereof as PTP1B inhibitor TORRENT PHARMACEUTICALS LTD (IN) 2008-09-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MEN1 4075/4885KMT2A 2895/4885POLB 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.